| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
We evaluated whether Lat Y136F knock-in mice, which show Th2 predominant immunoreaction with increased serum IgG1, a counterpart of human IgG4, are a novel mice model for IgG4-related disease (IgG4-RD). Lat Y136F knock-in mice showed a similar pathology to that of human IgG4-RD in kidney, pancreas and salivary glands, and a good response to corticosteroid. These results suggested that Lat Y136F knock-in mice are a novel mice model for IgG4-RD. Next, we analyzed the role of APRIL in IgG4-RD using Lat Y136F knock-in mice. We administered APRIL blocking antibody to Lat Y136F knock-in mice, and found that the inflammation in kidney in an APRIL blocking antibody group was significantly decreased as compared to that in a control group. This result indicated that APRIL plays some role in the promotion of lesions at least in IgG4-related kidney disease.
|
